Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.

Abstract: Systems and methods for evaluating and improving overall mental health of an individual are presented herein. In one or more examples, the systems and methods can be implemented in a computer application that is configured to download information from a user's mobile device. Once the data is acquired, in one or more examples, the application can prompt the user to provide additional information, and using both the user's input and the acquired data, the application can calculate a metric known as “Return on Happiness” (ROH) which can provide the user with a quantative measure of their happiness. In one or more examples, the ROH metric can be based on neurotransmitter activity in the user that is estimated by the application. The application can further identify any deficiencies in ROH and suggest one or more activities that the user can engage in to mitigate any of the detected deficiencies.

Abstract: Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.

Abstract: A method and system for providing stimulation to a user, the method including: transitioning a stimulation device from a baseline state to a first impedance monitoring state; during the first impedance monitoring state, guiding, an adjustment of a position of the stimulation device at a head region of the user to satisfy a first impedance criterion; upon satisfaction of the first impedance criterion, transitioning the stimulation device from the first impedance monitoring state to a stimulation regime that comprises a second monitoring state having a second criterion; upon detection of failure to satisfy the second criterion, transitioning the stimulation device from the stimulation regime to the first impedance monitoring state; and upon detecting that a third impedance criterion of the first impedance monitoring state is satisfied, transitioning the stimulation device from the first impedance monitoring state to the stimulation regime.

Abstract: The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Abstract: A method and system is provided for administering a Repetitive Transcranial Magnetic Stimulation (rTMS) or Transcranial Alternating Current Stimulation (tACS) at a pulse interval of is set equal to the period of a curve that best fits a section of a person's electroencephalogram (EEG) recorded before the pulse train.

Abstract: Provided herein are methods for predicting characteristics, such as activity, function and/or differentiation state of an in vitro population of neuronal cells, for instance a population of neuronal progenitor cells, as well as methods for selecting and/or implanting an in vitro population of neuronal progenitor cells having desired characteristics. Also provided herein are computing devices for performing the provided methods as well as related compositions, articles of manufacture, and kits, including for use in methods of treating a subject having a neurodegenerative disease, for instance Parkinson's disease.

Abstract: Provided herein are methods for predicting characteristics, such as activity, function and/or differentiation state of an in vitro population of neuronal cells, for instance a population of neuronal progenitor cells, as well as methods for selecting and/or implanting an in vitro population of neuronal progenitor cells having desired characteristics. Also provided herein are computing devices for performing the provided methods as well as related compositions, articles of manufacture, and kits, including for use in methods of treating a subject having a neurodegenerative disease, for instance Parkinson's disease.

Abstract: Described herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditions associated with EP2 activity.

Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (1).

Abstract: The present disclosure provides adeno-associated vector (AAV)-based methods of increasing gene expression of a GBA1 in floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or glial cells, including those differentiated from pluripotent stem cells, and methods of lineage specific differentiation of the same. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.

Abstract: A system for delivering electrical stimulation includes a control system and a stimulation stack. Additionally or alternatively, the system can include and/or be configured to interface with any or all of: an electrical stimulation device, a user device, a client application, and/or any other suitable components. A method for delivering electrical stimulation includes receiving an input and delivering electrical stimulation based on an electrical stimulation plan.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: An apparatus and method configured to control a brain stimulation device. The apparatus and method include a brain stimulation apparatus including, an input unit configured to receive at least one biological metric measurement value of a user, a neural network unit configured to determine a treatment pulse frequency equal to a weighted sum of the at least one biological metric measurement value of the user, wherein the weighted sum includes a plurality of weighting factors corresponding to each of the at least one biological metric measurement values, and wherein the plurality of weighting factors are determined based on optimized outcome results from previous administered treatments using treatment pulse frequencies determined by previous weighting factors, and a control unit configured to control a motor to operate at the treatment pulse frequency determined.

Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

Abstract: Systems and methods for evaluating and improving overall mental health of an individual are presented herein. In one or more examples, the systems and methods can be implemented in a computer application that is configured to download information from a user's mobile device. Once the data is acquired, in one or more examples, the application can prompt the user to provide additional information, and using both the user's input and the acquired data, the application can calculate a metric known as “Return on Happiness” (ROH) which can provide the user with a quantative measure of their happiness. In one or more examples, the ROH metric can be based on neurotransmitter activity in the user that is estimated by the application. The application can further identify any deficiencies in ROH and suggest one or more activities that the user can engage in to mitigate any of the detected deficiencies.

Abstract: The present invention provides anti-TREM2 antibodies, formulations thereof, and methods of use thereof.

Abstract: Clot engagement element comprising bundle of unwoven fibers can be assembled to form an acute stroke treatment device. The device has the capability of forming a three dimensional filtration matrix comprising effective pores with a distribution of sizes. The bundle of fiber design allows the device to be effectively delivered into circuitous cerebral arteries to remove clot that causes stroke. The fiber bundle based filtration matrix offers the advantages of conforming to the changing inner perimeter of a blood vessel during a clot removal process and thus the capability to effectively retain and remove a clot in the vessel. The filtration matrix offers the additional advantage to trap any break-off of the clot during the removal process. A plurality of fiber bundles can be combined to form an effective clot engagement element. Supplemental engagement structure as well as mechanical treatment structure can be integrated into the stroke treatment device.

Abstract: Systems for less invasive medical procedures comprise a filter device mounted on an integrated guiding structure and an aspiration catheter. These components can be used together or separately, and the system can be used with other medical devices that are designed for less invasive procedures, such as procedures in a patient's vasculature. The catheter can have a radiopaque band that is held in place under metal wire embedded within the polymer forming the tube of the catheter. In some embodiments, the aspiration catheter has a small diameter distal portion that can access into small diameter vessels in which the distal portion has a smaller average diameter than the remaining tube of the catheter.

Abstract: Neurophysiologic assessment system includes an ingestion data hub for generating clean data from heart rhythm data, a neuroscience processing unit for generating primary metrics from the clean data, a contextual analysis unit for receiving and analyzing external contextual data, a behavior analysis unit for generating secondary metrics from the clean data, primary metrics, and external contextual data, and a workflow management unit for controlling the ingestion data hub, and neuroscience processing, contextual analysis, and behavior analysis units. Secondary metrics include at least one of emotional wellbeing, energy, mood, and peak immersion value for a given time frame.